Improvement in overall and cancer‐specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients-Reference-Cited by-同舟云学术

Improvement in overall and cancer‐specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients

Published:2021-09-15 Issue:16 Volume:81 Page:1374-1381
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Hoeh Benedikt¹²^ORCID,Würnschimmel Christoph²³^ORCID,Flammia Rocco S.²⁴,Horlemann Benedikt²,Sorce Gabriele²⁵,Chierigo Francesco²⁶,Tian Zhe²,Saad Fred²,Graefen Markus³,Gallucci Michele⁴,Briganti Alberto⁵,Terrone Carlo⁶,Shariat Shahrokh F.⁷⁸⁹¹⁰¹¹,Tilki Derya³¹²^ORCID,Kluth Luis A.¹,Mandel Philipp¹,Chun Felix K. H.¹,Karakiewicz Pierre I.²

Affiliation:

1. Department of Urology, University Hospital Frankfurt Goethe University Frankfurt am Main Frankfurt am Main Germany

2. Division of Urology, Cancer Prognostics and Health Outcomes Unit University of Montréal Health Center Montréal Québec Canada

3. Martini‐Klinik Prostate Cancer Center University Hospital Hamburg‐Eppendorf Hamburg Germany

4. Department of Maternal‐Child and Urological Sciences Policlinico Umberto I Hospital, Sapienza Rome University Rome Italy

5. Division of Experimental Oncology, Unit of Urology, Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy

6. Department of Surgical and Diagnostic Integrated Sciences (DISC) University of Genova Genova Italy

7. Department of Urology, Comprehensive Cancer Center Medical University of Vienna Vienna Austria

8. Department of Urology Weill Cornell Medical College New York New York USA

9. Department of Urology University of Texas Southwestern Dallas Texas USA

10. Department of Urology, Second Faculty of Medicine Charles University Prague Czech Republic

11. Institute for Urology and Reproductive Health I. M. Sechenov First Moscow State Medical University Moscow Russia

12. Department of Urology University Hospital Hamburg‐Eppendorf Hamburg Germany

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24235

Reference20 articles.

1. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

2. Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old

3. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

4. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

5. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting;Journal of the American Geriatrics Society;2024-06-26

2. Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany;European Urology Focus;2024-03

3. Descriptive analysis of prostate cancer pathology data from diagnosis and surgery in men from the 45 and Up Study;Pathology;2024-02

4. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review;Prostate Cancer and Prostatic Diseases;2023-07-08

5. Comparison of peri- and intraoperative outcomes of open vs robotic-assisted partial nephrectomy for renal cell carcinoma: a propensity-matched analysis;World Journal of Surgical Oncology;2023-06-22